Protagen

The company's core technology revolves around its SeroTag® biomarker platform, which is used to develop powerful diagnostic tests. This platform aids in the differential diagnosis of autoimmune diseases that have complex and overlapping symptoms, such as rheumatoid arthritis. By identifying disease-specific autoantibodies, Protagen's tools enable earlier and more precise diagnoses, which can lead to better patient outcomes. For instance, their technology can help differentiate rheumatoid arthritis from other inflammatory joint diseases.

In the realm of immuno-oncology, Protagen has worked on identifying biomarkers that can predict a patient's response to cancer immunotherapies. This is a critical area in cancer treatment, as it helps clinicians select the most effective therapies for individual patients, moving towards a more personalized medicine approach. This capability allows for the stratification of patients in clinical trials and the development of companion diagnostics.

Protagen was acquired by the Oncimmune Holdings plc in 2019 for £5.7 million. This acquisition integrated Protagen's biomarker discovery capabilities, particularly in autoimmune diseases, with Oncimmune's focus on cancer diagnostics and immunotherapy. Following the acquisition, the German operations continued in Dortmund.